Pharmaceutical giant AstraZeneca's agreement to sell much of its antibiotics business won't impact operations at MedImmune, its Gaithersburg-based research and development arm, officials confirmed Wednesday.
MedImmune's infectious disease and vaccine portfolio for AstraZeneca (NYSE: AZN) is focused exclusively on biologics, while AstraZeneca's deal with Pfizer Inc. ' worth up to $1.6 billion ' is specific to its small molecule antibiotics business. Additionally, there is no production in AstraZeneca's...